Xu, Z., Wang, X., Chen, X., Zeng, S., Gong, Z., & Yan, Y. (2020). Pembrolizumab as the first-line monotherapy for non-small-cell lung cancer with a low programmed death ligand 1 threshold. J Cell Commun Signal.

Xu, Zhijie, Xiang Wang, Xi Chen, Shuangshuang Zeng, Zhicheng Gong, e Yuanliang Yan. "Pembrolizumab As the First-line Monotherapy for Non-small-cell Lung Cancer With a Low Programmed Death Ligand 1 Threshold." J Cell Commun Signal 2020.

Xu, Zhijie, et al. "Pembrolizumab As the First-line Monotherapy for Non-small-cell Lung Cancer With a Low Programmed Death Ligand 1 Threshold." J Cell Commun Signal 2020.